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Flemingia macrophylla (Leguminosae) is a popular traditional remedy used in Taiwan as anti-inﬂammatory, promoting blood
circulation and antidiabetes agent. Recent study also suggested its neuroprotective activity against Alzheimer’s disease. Therefore,
the eﬀects of F. macrophylla on Aβ production and degradation were studied. The eﬀect of F. macrophylla on Aβ metabolism was
detected using the cultured mouse neuroblastoma cells N2a transfected with human Swedish mutant APP (swAPP-N2a cells). The
eﬀects on Aβ degradation were evaluated on a cell-free system. An ELISA assay was applied to detect the level of Aβ1-40 and Aβ1-
42. Western blots assay was employed to measure the levels of soluble amyloid precursor protein and insulin degrading enzyme
(IDE). Three fractions of F. macrophylla modiﬁed Aβ accumulation by both inhibiting β-secretase and activating IDE. Three
ﬂavonoids modiﬁed Aβ accumulation by activating IDE. The activated IDE pool by the ﬂavonoids was distinctly regulated by
bacitracin (an IDE inhibitor). Furthermore, ﬂavonoid 94-18-13 also modulates Aβ accumulation by enhancing IDE expression. In
conclusion, the components of F. macrophylla possess the potential for developing new therapeutic drugs for Alzheimer’s disease.
1.Introduction
Flemingia macrophylla (Leguminosae) is a popular tradi-
tional remedy used in Taiwan [1] and India [2]. The stems or
leaveshavebeenusedasananti-inﬂammatory,bloodcircula-
tionpromotionandantidiabeticagent,allofwhichwererele-
vant to the pathogenesis of Alzheimer’s disease (AD). Recent
research has suggested its neuroprotective activity against
amyloidβ (Aβ)[3],hepatoprotectiveactivity[4],antiinﬂam-
matory activity [5], and antiosteoporosis activity [6].
AD is a complex mental illness characterized by the
accumulation of extracellular senile plaques and intracel-
lular neuroﬁbrillary tangles. Senile plaques are composed
of deposited Aβ, derived from the processing of amyloid
precursorprotein(APP)bytwoenzymes:β-siteAPPcleaving
enzyme (BACE or β-secretase) and γ-secretase [7]. Accord-
ing to the amyloid hypothesis, abnormal accumulation of Aβ
in the brain is the primary causative factor contributing to
AD pathogenesis, whereby the disease process is believed to
result from an imbalance between Aβ production (anabolic
activity) and clearance (catabolic activity) [8–10]. APP
molecules are cleaved by secretases at the cell surface, the
Golgi complex, and along the endosomal/lysosomal pathway
[11, 12]. Most cell surface β-secretase is reinternalized into
early endosomal compartments, from where it can be recy-
cled back to the cell surface or later be redirected to endoso-
mal/lysosomal compartments and/or to the trans-Golgi [13].
It is generally believed that removal of Aβ from the brain
might be of great therapeutic beneﬁt [14]. Consequently,
therapeutic strategies aiming to decrease Aβ levels, such
as inhibition of either β-secretase or γ-secretase and Aβ
immunization, are currently a major focus of AD research
[15–17].MuchmoreattentionhasbeenpaidtoabnormalAβ
production, but recently, the role of Aβ degradation in Aβ2 Evidence-Based Complementary and Alternative Medicine
homoeostasis has been increasingly recognized, as several
enzymes that degrade Aβ have been identiﬁed, such as
insulin degrading enzyme (IDE), neprilysin (NEP), and
matrix metalloproteins (MMPs) [18].
Clinical and epidemiological studies have found that
type 2 diabetes and hyperinsulinemia increased the risk of
developing AD, and the link between these two diseases may
be IDE [19, 20]. IDE is a zinc metalloendopeptidase that
is highly expressed in the liver, testis, muscle, and brain.
Although it is predominantly cytosolic, a secreted form of
IDE in extracellular compartments such as cerebrospinal
ﬂuid was also identiﬁed [21]. IDE degrades a wide range of
substrates that include insulin, amylin, insulin-like growth
factors, and Aβ [18]. Furthermore, previous work has
reported that the IDE level in AD is reduced [22].
In this study, we investigate the eﬀect of F. macrophylla
extracts or isolated pure compounds on Aβ accumulation
and found that they decrease extracellular accumulation
of Aβ1-40 in the cultured mouse neuroblastoma cells N2a
transfected with human Swedish mutant APP (swAPP-N2a
cells) by inhibiting β-secretase or enhancing Aβ degradation.
2. Methods
2.1. Reagents. Medium for cell culture, heparin, Lipofec-
tamine, and human β amyloid 1-40 and 1-42 kits were pur-
chased from Invitrogen (Carlsbad, CA, USA). Mouse anti-
actin antibody and anti-IDE polyclonal antibody, rabbit
polyclonal anti-APP (KPI domain) antibody, and synthetic
Aβ1-40 were purchased from Millipore (Billerica, MA,
USA). Anti-Aβ1-17 antibody (clone 6E10) was from Signet
(Dedham, MA). Enhanced chemiluminescence detection
reagents, anti-rabbit and anti-mouse IgG antibody conju-
gated with horseradish peroxidase were obtained from GE
Healthcare (Buckinghamshire, UK). Insulin, progesterone,
putrescine, sodium selenite, and transferrin were purchased
from Sigma (St. Louis, MO, USA). All other reagents were
purchased from Sigma (St. Louis, MO, USA) or Merck
(Darmstadt, Germany).
2.2.PlantMaterial,Extraction,andIsolation. Theaerialparts
of F. macrophylla were collected from Kaohsiung County,
Taiwan in May, 2002. The plant was identiﬁed by Mr. Jun-
Chih Ou, former associate investigator of National Research
Institute of Chinese Medicine, and comparison with the
voucher specimens was deposited earlier at the Herbarium
of the Department of Botany, National Taiwan University,
Taipei, Taiwan (no. TAI219262, April, 1988). The extraction
andisolationofeachfractionforthisassayislistedinTable 1,
and the structure and chemical name of the ﬂavonoids
isolated from F. macrophylla were displayed in Figure 1.
2.3. Cell Culture and Transfection. Neuro-2a (N2a) cells were
cultured in minimal essential medium (MEM) containing
10% fetal bovine serum (FBS). Conﬂuent 90% N2a cells
were transfected with plasmid containing human Swedish
mutant of amyloid precursor protein (pCGR/APP770)b y
using Lipofectamine 2000. After transfection for 6h, the cells
Table 1: Extraction and isolation of F. macrophylla. The ground
aerial parts of F. macrophylla (12kg) were extracted following the
protocol, and the fractions were named.
Fraction
name The protocol of extraction and fractionation
EtOH
The aerial parts of F. macrophylla were extracted three
times with 95% ethanol (EtOH) at 60◦C overnight.
The combined EtOH extract was evaporated under
reduced pressure.
H2O EtOH extract was taken up in water as water-soluble
fraction.
H25M
H50M
H75M
H100M
The water-soluble fraction (H2O) was
chromatogramed over Diaion HP-20 column and
eluted with 25%-, 50%-, 75%-, and 100%-methanol
to give four fractions: H25M, H50M, H75M, and
H100M, respectively.
EA
n-BuOH
The water-soluble fraction (H2O) was partitioned
with ethyl acetate and n-butanol successively to get
two fractions: EA and n-BuOH, respectively.
B25M
B50M
B75M
B100M
The n-BuOH fraction was chromatogramed over
Diaion HP-20 column and eluted with 25%-, 50%-,
75%-, and 100%-methanol to give four fractions:
B25M, B50M, B75M, B100M, respectively.
EA-n
EA and n-BuOH fractions were subjected to silica gel
column chromatography using a
hexane-EA-methanol gradient and EA-methanol
gradient, respectively. Eleven fractions were collected
as EA-n (n = 4, 35, 52, 55, 74, 79, 85, 94, 103, 121,
165).
Flavonoids
The fractions rich in ﬂavonoids were separated ﬁrst
over a silica gel column with a 25%–60% EA/hexane
gradient as eluent and then over Sephadex LH-20
columns with EA or methanol to aﬀord ﬂavonoids.
were incubated with chemical deﬁned medium (DMEM/F12
medium containing 5mM Hepes pH 7.4, 0.6% glucose,
2.5mMglutamine,3mMNaHCO3,100μg/mL,transferring,
20nM progesterone, 60μM putrescine, 30nM sodium selen-
ite, 2μg/mL heparin, and 100nM insulin) for 20h. For treat-
ment with cells, the fractions or ﬂavanoids of F. macrophylla
were introduced into the chemical deﬁned medium.
2.4. MTT Assay. The reduction of 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) was used to
evaluate cell viability. Cells were incubated with 0.5mg/mL
MTT for 1h. The formazan particles were dissolved with
DMSO. OD600nm was measured using an ELISA reader.
2.5. The Cell-Free Assay of Aβ1-40 Degradation. The con-
ditioned medium of N2a cells containing the proteases to
degrade Aβ was collected and used for the cell-free assay
of Aβ degradation. Ten ng of synthetic Aβ1-40 (Invitrogen,
03-138) were added into 300μL N2a-conditioned medium
containing various reagents and incubated at 37◦Cf o r2 4h .
The remaining Aβ were then quantiﬁed by ELISA assay
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Figure 1: The structure and chemical name of the ﬂavonoids isolated from F. macrophylla.
2.6. Quantiﬁcation of Aβ1-40 in Cells and Culture Medium.
After treatment, culture media and cell were collected sep-
arately and subjected to determining the levels of Aβ1-40
using assay kits. The detailed experiments were performed
according to the manufacturer’s protocol.
2.7. Immunoblotting. After treatment, culture media were
collected and cells were washed with ice-cold phosphate
buﬀered saline (PBS) three times. Cells were harvested
in lysis buﬀer (50mM Hepes pH7.5, 2.5mM EDTA,
1mM phenylmethylsulfonyl ﬂuoride, 5μg/mL aprotinin,
and 10μg/mL leupeptin), and cell lysates were prepared.
E q u a lp r o t e i na m o u n t so fc e l ll y s a t ea n de q u a lv o l u m e
of culture medium were subjected to SDS-polyacrylamide
gel electrophoresis and immunoblotting. Fujiﬁlm LAS-3000
(Tokyo, Japan) was used to detect and quantify the immuno-
reactive protein.
2.8. Statistical Analysis. Results are expressed as mean ±
SD and were analyzed by ANOVA with post hoc multiple
comparisons with a Bonferroni test.
3. Results
3.1. The Eﬀects of Insulin and Bacitracin on Aβ1-40 Level in
swAPP-N2a Cells Culture. To determine the importance of
IDE activity on the levels of both extracellular and intracel-
lular Aβ1-40 in swAPP-N2a cell culture, various concentra-
tionsofinsulin(thesubstrateofIDE)and/or2nMbacitracin
(a competitive inhibitor of IDE) were subjected into swAPP-
N2a cell culture, and the Aβ1-40 accumulation was assayed.
The results showed that insulin promotes Aβ1-40 accumu-
lation in a concentration-dependent manner. Extracellular
Aβ1-40 was hardly detected (i.e., 0.88 ± 1.07ng/mL) in
the culture medium without containing insulin. Insulin at4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: The eﬀect of insulin and bacitracin on the level of
extracellular and intracellular Aβ1-40. APP-transfected N2a cells
were treated with indicated concentrations of insulin and bacitracin
for 20h. The level of extracellular (a) and intracellular (b) Aβ1-
40 was determined by ELISA. Results are means ± SD from three
independent experiments. Signiﬁcant diﬀerences between control
and treated cells are indicated by ∗P<0.05, ∗∗∗P<0.001.
10, 100, 1000, and 4200nM increased the level of extra-
cellular Aβ1-40 to 3.70 ± 2.18ng/mL, 14.78 ± 2.17ng/mL,
23.38 ± 1.83ng/mL, and 26.02 ± 1.45ng/mL, respectively
(Figure 2(a)). The results suggested that about 26ng/mL
of extracellular Aβ1-40 in the cultured medium regulated
by insulin sensitive peptidase(s), including IDE. Therefore,
bacitracin was employed to verify the IDE-sensitive pool of
extracellular Aβ1-40 in the cultured medium. The results
showed that 2nM bacitracin increased the level of extracel-
lular Aβ1-40 to 10.66±1.32ng/mL (Figure 2(a)), and higher
concentrationofbacitracin did not signiﬁcantly enhance this
eﬀect, suggesting that about 11ng/mL of extracellular Aβ1-
40 in the cultured medium was regulated by IDE.
Insulin may regulate the extracellular Aβ1-40 by enhanc-
ing exocytosis of the intracellular Aβ1-40. Therefore, the
level of intracellular Aβ1-40 was assayed. The results showed
that the level of intracellular Aβ1-40 was concentration
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Figure 3: The eﬀect of insulin and bacitracin on Aβ1-40 degrada-
tion in the N2a-conditioned medium. Aβ1-40 (10ng) were incu-
bated in the N2a-conditioned medium with indicated concentra-
tions of insulin and bacitracin, at 37◦C for 16h. The level of
remaining Aβ1-40 was determined by ELISA. Results are means ±
SD from three independent experiments. Signiﬁcant diﬀerences
between control and FM fractions-treated cells are indicated by
∗∗∗P<0.001.
dependently reduced by insulin, but not by bacitracin
(Figure 2(b)). The results suggested that insulin may pro-
mote the level of extracellular Aβ1-40 by inhibiting IDE
and by accelerating the exocytosis of intracellular Aβ1-
40. Alternately, bacitracin did not aﬀect the exocytosis of
intracellular Aβ1-40. The similar eﬀects of insulin and
bacitracin were found on Aβ1-42 (data not shown).
3.2. The Eﬀects of Insulin and Bacitracin on the Degradation
of Synthetic Aβ1-40 in the N2a-Conditioned Medium. For
bypassing the involvement of Aβ anabolic and traﬃcking
pathway, a cell-free Aβ degradation assay using N2a cell-
conditioned medium as the source of secreted protease and
the synthetic Aβ1-40 was employed as the substrate. The
results showed that Aβ degradation was inhibited by insulin
in a concentration-dependent manner (Figure 3). The added
synthetic Aβ1-40 (10ng) was degraded to 0.83 ± 0.17ng in
the conditioned medium without containing insulin, and 10,
100, and 1000nM insulin increased the level of remaining
Aβ1-40 to 3.65±0.82ng, 7.13±0.55ng, and 10.34±1.11ng,
respectively, indicating that the degradation of 10ng Aβ was
completely abolished by 1μM insulin (Figure 3). Treatment
with 2nM, 5nM bacitracin, or 2nM bacitracin combined
with 100nM insulin increased the remaining level of Aβ1-
40 to 4.83±0.96, 5.51±0.65, and 9.81±0.35ng, respectively
(Figure 3), suggesting a synergism of insulin and bacitracin
on inhibiting Aβ degradation.
3.3. The Eﬀects of the Fractions and Flavonoids Isolated from F.
m a c r o p h y l l ao nt h eL e v e lo fA β1-40. To determine the eﬀects
of the fractions and ﬂavonoids isolated from F. macrophylla
on the level of extracellular Aβ1-40, the cell toxicity of the
fractions and ﬂavonoids was detected, and was then the
subtoxic concentration (STC) of the fractions and ﬂavonoidsEvidence-Based Complementary and Alternative Medicine 5
Table 2: The eﬀects of the fractions of F. macrophylla on the levels
of extracellular and intracellular Aβ1-40. APP-transfected N2a cells
were treated with the fractions of F. macrophylla at the STC for 20h.
The level of extracellular and intracellular Aβ1-40 was determined
by ELISA. Results are means ± SD from three independent
experiments. Signiﬁcant diﬀerences between control and fractions-
treated cells are indicated by ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<
0.001.
Fractions
STC
(μg/mL)
Aβ1-40 (% of control)
Extracellular Intracellular
EtOH 10 46.18 ±8.19∗∗∗ 94.92 ±21.28
H2O 100 28.16 ±7.38∗∗∗ 155.62 ±13.79∗∗∗
H25M 1 78.70 ±5.21∗ nda
H50M 1 86.05 ±24.57 nd
H75M 50 13.75 ±5.56∗∗∗ 212.47 ±47.25∗∗∗
H100M 1 69.98 ±13.68∗∗ nd
BuOH 1 63.49 ±8.09∗∗∗ nd
B25M 1 66.19 ±18.86∗ nd
B50M 10 18.66 ±2.77∗∗∗ 100.36 ±16.35
B75M 50 9.40 ±3.05∗∗∗ 238.75 ±60.32∗∗∗
B100M 50 64.95 ±9.02∗∗ nd
EA 1 124.57 ±35.93 nd
EA-1 10 55.16 ±6.27∗∗ nd
EA-4 1 119.70 ±24.55 nd
EA-35 10 71.64 ±13.65∗ nd
EA-52 1 64.57 ±6.94∗ nd
EA-55 1 54.14 ±22.13∗∗ nd
EA-74 1 52.65 ±12.65∗∗ 96.21 ±4.71
EA-79 1 107.02 ±10.67 nd
EA-85 1 111.94 ±26.00 nd
EA-94 1 98.63 ±27.61 nd
EA-103 1 77.66 ±4.73∗ nd
EA-121 1 60.82 ±18.82∗∗ nd
EA-165 1 69.57 ±19.16∗ nd
and, not determined.
was subjected into the extracellular Aβ1-40 accumulation
assay. The results indicated that ﬁve highly polar fractions
(i.e., EtOH, H2O, H75M, B50M, and B75M) attenuated the
accumulation of medial Aβ1-40 by more than 50% (Table 2).
Among the lesser polar fractions, EA-74 is the most eﬀective
fraction which attenuated the accumulation of medial Aβ1-
40 to 52.62 ± 12.56% of control (Table 2). Three ﬂavonoids
(i.e.,49-2,52-11,and94-18-13)attenuatedtheaccumulation
of extracellular Aβ1-40 by more than 30% (Table 3).
The eﬀects of the fractions and ﬂavonoids on the
intracellular Aβ1-40 accumulation were further evaluated.
The result showed that the fraction H2O, H75M, and B75M
elevated the intracellular level of Aβ1-40 to 155.6 ± 13.4,
213.5 ± 47.3, and 238.8 ± 60.3% of the control, respectively,
and the fraction EtOH, B50M, and EA-74 and the ﬂavonoid
49-2, 52-11, and 94-18-13 did not exert signiﬁcant eﬀects
on the intracellular Aβ1-40 accumulation (Tables 2 and 3).
Those were therefore selected for further investigation.
Table 3: The eﬀects of the ﬂavonoids isolated from F. macrophylla
on the levels of extracellular and intracellular Aβ1-40. APP-
transfected N2a cells were treated with the ﬂavonoids at STC for
20h. The level of extracellular and intracellular Aβ1-40 was deter-
mined by ELISA. Results are means ± SD from three independent
experiments. Signiﬁcant diﬀerences between control and ﬂavonoid-
treated cells are indicated by ∗P<0.05, and ∗∗P<0.01.
Flavonoid
STC
(μg/mL)
Aβ1-40 (% of control)
Extracellular Intracellular
49-3 0.1 66.93 ±11.16∗ 96.03 ± 5.64
52-11 0.1 65.41 ±16.90∗ 99.36 ± 9.81
85-29 0.1 94.26 ±18.15 nd
92-26 1 87.00 ±29.13 nd
94-18-13 0.1 56.83 ±7.52∗∗ 104.23 ± 12.40
and, not determined.
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Figure 4: The eﬀects of the fractions and ﬂavonoids of F. macro-
phylla on Aβ1-40 degradation in the N2a-conditioned medium.
Aβ1-40 (10ng) were incubated in the N2a-conditioned medium
with 100nM insulin and the fractions and ﬂavonoids of F.
macrophylla at NTC, 37◦C for 20h. The level of remaining Aβ1-
40 was determined by ELISA. Results are means ± SD from three
independent experiments. Signiﬁcant diﬀerences between control
and the treated cells are indicated by ∗∗P<0.01, ∗∗∗P<0.001.
3.4. The Eﬀects of the Fractions and Flavonoids Isolated from
F. macrophylla on the Aβ1-40 Degradation in the N2a-
Conditioned Medium. The fraction EtOH, EA-47, B50M,
and ﬂavonoid 49-3, 52-11, and 94-19-13 decreased the
remainingsyntheticAβ1-40to82.66±1.26%, 83.25±0.74%,
83.50 ± 7.30%, 76.02 ± 4.88%, 83.24 ± 8.60%, and 82.31 ±
8.04% of the control, respectively (Figure 4). The results
suggesting that the fractions and ﬂavonoids may ameliorate
Aβ accumulation by promoting Aβ degradation. The similar
eﬀects were found on Aβ1-42 (data not shown).
3.5. The Level of Secreted IDE Was Promoted by Flavonoid
94-18-13. Treatment with the fraction B50M, EA-74, and6 Evidence-Based Complementary and Alternative Medicine
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Figure 5:ThelevelofIDEwasdiﬀerentiallyaﬀectedbythefractions
and ﬂavonoids of F. macrophylla. N2a cells were treated with
fractions and ﬂavonoids for 20h at NTC. The level of IDE in cell
lysate and medium was determined by immunoblotting. The upper
panel is the representative blot. The lower panel is the relative
level of IDE in cell lysate (closed column) and medium (opened
column) exhibited as percentage of the control. Results are means
± SD from three independent experiments. Signiﬁcant diﬀerences
between control and the treated cells are indicated by ∗P<0.05,
∗∗P<0.01 and ∗∗∗P<0.001.
ﬂavonoid 49-2, 52-11, and 94-18-13 attenuated the level
of cellular IDE by about 20%, whereas the fraction EtOH
failed to show signiﬁcant eﬀect on the level of cellular
IDE (Figure 5). Treatment with the faction B50M and EA-
74 eliminated the level of medial IDE by 21.3 ± 12.0a n d
26.6 ± 9.9%, respectively. On the contrary, ﬂavonoid 94-
18-13 increased the level of medial IDE to 146.9 ± 16.7%
of the control. The result suggested that only ﬂavonoid 94-
18-13 may accelerate Aβ degradation by promoting IDE
expression. The change in enzyme activity may also be
involved although it is not detected in this study.
3.6. The Recovery Eﬀect of Bacitracin on the Treatment-
Reduced Accumulation of Extracellular Aβ1-40. The promot-
ingactivityofthefractionsandﬂavonoidsonAβdegradation
by IDE may include bacitracin-sensitive and -insensitive
pools. The bacitracin-sensitive pools in the cultures treated
with the fraction EtOH, EA-74, B50M, and ﬂavonoid 94-19-
13 were 10.71, 10.83, 11.35, and 11.29ng/mL, respectively
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Figure 6: Aβ1-40 accumulation reduced by the fractions and
ﬂavonoids was diﬀerentially recovered by bacitracin. (a) swAPP770-
transfected N2a cells were treated with the fractions and ﬂavonoids
for 20h at NTC, in the absence (closed columns) and presence
(opened columns) of 2nM bacitracin. The level of extracellular
Aβ1-40 was determined by ELISA. (b) The recovery eﬀect of
bacitracin was calculated by the subtraction between the levels of
the cells treated with and without bacitracin. Results are means ±
SD from three independent experiments. Signiﬁcant diﬀerences
between control and FM fractions-treated cells are indicated by
∗∗∗P<0.001.
(Figure 6). The results suggested that these treatments did
not aﬀect the bacitracin-sensitive pool. The bacitracin-
sensitive pools in the cultures treated with the ﬂavonoid
49-3 and 52-11 were 7.18 and 14.05ng/mL, suggesting that
ﬂavonoid 49-3 and 52-11 reduce and enhance the bacitracin-
sensitive pool, respectively.
3.7. The Level of Soluble APPβ Was Decreased by the Fractions
of F. macrophylla. The anabolic pathway of Aβ may also be
aﬀected by the fractions of F. macrophylla which resulted inEvidence-Based Complementary and Alternative Medicine 7
the decrease of extracellular Aβ. Two categories of soluble
APP (sAPP) including α-secretase-derived sAPP (sAPPα)
and β-secretase-derived sAPP (sAPPβ)m a yb ed e t e c t e di n
the swAPP-N2a-conditioned medium. Two antibodies were
used to detect these two sAPPs. The anti-Aβ1-17 (6E10)
antibody may recognize sAPPα (this fragment contains Aβ1-
17), and the anti-APP (KPI domain) antibody may recognize
both sAPPα and sAPPβ on immunoblot. The result showed
that 6E10 antibody-recognized sAPPα was not signiﬁcantly
aﬀected by the fractions of F. macrophylla. By contrast, the
anti-APP (KPI domain) antibody-recognized sAPPα and
sAPPβ were signiﬁcantly decreased. The fractions of EtOH,
EA-47, and B50M decreased the level of sAPPs to 76.73 ±
9.11%, 78.99 ± 7.02%, and 79.44 ± 8.48%, respectively. The
result indicated that the fractions may inhibit the activity of
β-secretase and then decrease the level of sAPPβ (Figure 7),
whichmayreﬂecttheeﬀectsofthesefractionsonattenuating
Aβ accumulation.
4. Discussion
It is generally believed that removal of Aβ from the brain
might be of great beneﬁt for AD therapy [14, 23]. To ﬁnd the
reagents which are capable of reducing Aβ levels is required
for improving the treatment of AD. Aβ level are determined
by the metabolic balance between anabolic and catabolic
activities. Among the catabolic enzymes, insulin degrading
enzyme (IDE) is thought to be the principal secreted enzyme
responsible for the degradation of Aβ in the extracellular
space [18, 21, 24]. An interesting link between insulin and
Aβ is that they both are IDE substrates [20, 25, 26], and
the patients with type 2 diabetes have an increased risk of
AD [27]. Since IDE is more eﬃcient on degrading insulin
than Aβ, the concomitant increase in insulin and Aβ levels
may lead to a redistribution of available IDE away from its
functionasanAβ-degradingenzyme[25].Thus,theinvolve-
ment of IDE on Aβ degradation in our experimental system
was veriﬁed by insulin and bacitracin, an IDE competitive
inhibitor [28], to promote Aβ accumulation. Aβ degradation
was completely abolished by 1μM Insulin, which was only
partially inhibited by bacitracin. The results suggesting that
I D Em a yb et h em a j o re n z y m ec o n t r i b u t et od e g r a d et h e
extracellular Aβ.
By using swAPP-N2a as cell model, we investigated the
eﬀects of F. macrophylla on reducing Aβ accumulation in the
present of 100nM insulin. Previous studies have indicated
that some herbal medicine-derived compounds reduced
Aβ accumulation in the similar cell models [29–33]. F.
macrophylla is a popular traditional remedy used in Taiwan
[1] and India [2]. The stems have been used in folk medicine
for antirheumatic and anti-inﬂammatory agent, promoting
blood circulation and antidiabetes. Our recent research
has suggested the AD-relative neuroprotective eﬀects of F.
macrophylla on the primary cultures of neonatal cortical
neurons against Aβ-mediated neurotoxicity [3]. However,
the eﬀect of F. macrophylla on Aβ accumulation and the
underlying mechanism has not been studied. To investigate
whether F. macrophylla aﬀects Aβ metabolism, we detect the
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Figure 7: The eﬀect of the fractions of F. macrophylla on the
level of secreted APP in swAPP770-transfected N2a cell. swAPP770-
transfected N2a cells were treated with the fractions for 20h at NTC
of 10, 1, and 10μg/mL, respectively. The level of 6E10 antibody-
stained sAPP (i.e., sAPPα) and KPI antibody-stained sAPPs (i.e.,
sAPPα plus sAPPβ) in conditioned medium was determined by
immunoblotting. The upper part is the representative image of
immunoblot. The lower part is the relative level of 6E10 antibody-
stained sAPPα (opened column) and KPI antibody-stained sAPPs
(closed column). Results are means ± SD from three independent
experiments. Signiﬁcant diﬀerences between control and FM
fractions-treated cells are indicated by ∗P<0.05.
extracellular and intracellular Aβ1-40 levels of the treated
swAPP-N2a cells by ELISA assay and found that fraction
EtOH, EA-74, and B50M and ﬂavonoid 49-3, 52-11, and
94-19-13 signiﬁcantly reduced the extracellular Aβ1-40 ac-
cumulation without promoting the intracellular Aβ1-40
accumulation.
SeveraltargetsitesincludingAβ anabolic,traﬃcking,and
catabolic pathways could be considered as the targets of the
fractions or ﬂavonoids on Aβ accumulation in swAPP-N2a
cells. Therefore, a cell-free Aβ degradation system using
N2a cell-conditioned medium as protease source and the
synthetic Aβ1-40 as subtract was used to bypass the involve-
ment of Aβ anabolic and traﬃcking pathway. The results
showed that Aβ degradation was inhibited by insulin in a
concentration-dependent manner. Aβ degradation was com-
pletely abolished by 1μM insulin. Bacitracin partially inhib-
ited the degradation of Aβ1-40 alone or combined with
insulin. It has been proposed that both microglia and8 Evidence-Based Complementary and Alternative Medicine
astrocytes secrete protease, including IDE that mediates the
degradation of Aβ in the extracellular milieu [21, 34]w h i c h
may be similar to our system.
Aβ degradation by IDE was promoted by the fractions
and ﬂavonoids. In the presence of 100nM insulin, the frac-
tions and ﬂavonoids decreased the remaining Aβ1-40 to
about 80% of the control. The results suggest that the frac-
tions and ﬂavonoids may ameliorate Aβ accumulation by
promoting Aβ degradation.
To study the mechanism underlying the eﬀectof the frac-
tions and ﬂavonoids on the level of IDE, we ﬁrst performed
western blot analysis to detect IDE expression. The results
showed that only ﬂavonoid 94-18-13 signiﬁcantly improved
IDE expression. Nevertheless, the underlying mechanism
required further investigation, although recent studies have
indicated that IDE expression may be regulated through liver
Xreceptor[35],NMDAreceptor[36],β2adrenergicreceptor
[37], insulin receptor [38], dopamine receptor [39], and
glucocorticoid receptor [40].
To study the eﬀect of the fractions and compounds on
the IDE-dependent degradation pool of extracellular Aβ,w e
then detected extracellular Aβ1-40 levels with ELISA after
treating swAPP-N2a cells with the fractions or ﬂavonoids
in the absence or presence of 2nM bacitracin. We found
that three fractions and ﬂavonoid 94-19-13 activated IDE
without aﬀecting the bacitracin-sensitive pool, which was
partiallycompressedand extended by ﬂavonoid 49-3 and 52-
11, respectively, through the allosteric regulatory eﬀect. In
the previous study, Cabrol et al. [41] discovered two small
molecule activators of IDE through high-throughput com-
pound screening. They established the putative ATP-binding
domain as a key modulator of IDE proteolytic activity. ATP
inhibits IDE-mediated insulin degradation at physiological
concentration [42]. On the other hand, ATP was found
to activate IDE-mediated ﬂuorogenic substrate by confor-
mational switch through its triphosphate moiety [43, 44].
Recently, the allosteric regulatory sites of IDE were identiﬁed
[45]. Therefore, the fractions and ﬂavonoids may activate
IDE by occupying the allosteric binding site.
To determine whether the fractions aﬀect Aβ anabolism,
the western blot of medial sAPPs (sAPPα and sAPPβ)w a s
performed. The results showed that all three fractions ame-
liorated the production of sAPPs but not sAPPα, suggesting
that sAPPβ was aﬀected by these three fractions through
inhibiting the activity of β- s e c r e t a s e .T h ep r e v i o u ss t u d i e s
havedemonstratedthatthetenuigeninisolatedfromPolygala
tenuifolia and berberine isolated from Coptidis rhizome can
inhibitthesecretionofAβ viaβ-secretaseinhibition[30–32].
5. Conclusion
The results suggested that the fraction EtOH, EA-74, and
B50M of F. macrophylla may modify Aβ accumulation by
both inhibiting β-secretase and activating IDE. The three
ﬂavonoids may modify Aβ accumulation by activating IDE.
The activated IDE poor by these three ﬂavonoids was dis-
tinctly regulated by bacitracin. Furthermore, ﬂavonoid 94-
18-13 also modulates Aβ accumulation by enhancing IDE
expression. Change in Aβ accumulation may prevent Aβ
aggregation and the subsequent neurotoxicity on AD. Such
information couldbe exploited to develop the new therapeu-
tic drugs for sporadic AD.
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